Re the 2021 update... I agree with Kiwi it’s a study follow-up for more data points. Patency-1 also had a two year follow up which should dredge up some interesting data towards the end of this year (two years after Patency-1 unblinding 2017).
I don’t read anything into it regarding trial success/failure. Patency-1 failed and yet they indicated in the published study they still intend to follow-up.
Expect data this week still.
And yes AMRN is a monster... if BP *tries* to buy now it’s gonna cost them dearly (triple digits)